Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
AUTOR(ES)
Coelho, Rafael Corrêa, Reinert, Tomás, Campos, Franz, Peixoto, Fábio Affonso, Andrade, Carlos Augusto de, Castro, Thalita, Herchenhorn, Daniel
FONTE
Int. braz j urol.
DATA DE PUBLICAÇÃO
2016-08
RESUMO
ABSTRACT Purpose: The aim of this study was to assess the impact of sunitinib treatment in a non-screened group of patients with metastatic renal cell cancer (mRCC) treated by the Brazilian Unified Health System (SUS) at a single reference institution. Material and Methods: Retrospective cohort study, which evaluated patients with mRCC who received sunitinib between May 2010 and December 2013. Results: Fifty-eight patients were eligible. Most patients were male 41 (71%), with a median age of 58 years. Nephrectomy was performed in 41 (71%) patients with a median interval of 16 months between the surgery and initiation of sunitinib. The most prevalent histological subtype was clear cell carcinoma, present in 52 (91.2%) patients. In 50 patients (86%), sunitinib was the first line of systemic treatment. The main adverse effects were fatigue (57%), hypothyroidism (43%), mucositis (33%) and diarrhea (29%). Grade 3 and 4 adverse effects were infrequent: fatigue (12%), hypertension (12%), thrombocytopenia (7%), neutropenia (5%) and hand-foot syndrome (5%). Forty percent of patients achieved a partial response and 35% stable disease, with a disease control rate of 75%. Median progression free survival was 7.6 months and median overall survival was 14.1 months. Conclusion: Sunitinib treatment was active in the majority of patients, especially those with low and intermediate risk by MSKCC score, with manageable toxicity. Survival rates were inferior in this non-screened population with mRCC treated in the SUS.
Documentos Relacionados
- Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
- Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
- Prognostic factors in renal cell carcinoma: analysis of 227 patients treated at the Brazilian National Cancer Institute
- Treatment of B Non-Hodgkin's Lymphoma in children: the experience of multicentre studies and Brazilian National Cancer Institute's experience
- Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute